Immorta Bio Joined Endless Frontier Labs Cohort
The Miami-based longevity startup has been selected for the nine-month mentorship program at NYU Stern.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Do university-backed startup incubators provide more value to new companies than independent business development?
Miami longevity company Immorta Bio has been selected to join the 2026-27 Endless Frontier Labs cohort. The startup develops the SenoMune and StemCellRevivify therapeutic platforms.
Why it matters
The program supports startups in scaling their operations by providing direct access to vital business and investment ecosystems. This milestone helps the company advance its clinical development goals.
The nine-month program provides technical support for Immorta Bio to advance its pipeline. The company focuses on developing its proprietary SenoMune and StemCellRevivify therapeutic platforms.
The players
Immorta Bio
This Miami-based scientific longevity company is dedicated to developing therapeutic platforms aimed at age-related cellular processes.
Endless Frontier Labs
Housed at NYU Stern, this program offers mentorship and access to business networks for science-based startups without taking equity.
The details
Immorta Bio receives guidance from serial entrepreneurs, investors, and technical mentors throughout the duration of the program. The initiative also connects founders with business coaches, scientists, and NYU students to help reach upcoming clinical milestones.
Timeline
Immorta Bio announced its selection to the program on September 23, 2026.
The current Endless Frontier Labs cohort runs throughout the 2026-2027 academic period.
The Tech Race
The involvement of Immorta Bio in the Endless Frontier Labs program at NYU Stern reflects a growing trend of academic-led support for deep-tech longevity startups. This positioning allows the company to leverage institutional expertise to compete in the expanding biotech sector.
The program helps accelerate the timeline for bringing novel longevity therapies into human clinical development. This process could eventually influence the availability of advanced medical treatments for aging-related conditions.
The takeaway
Selecting into high-level accelerator programs serves as a strategic validator for biotech firms seeking to bridge the gap between laboratory research and clinical reality. Mentorship from seasoned entrepreneurs can prove as essential as capital when preparing for the regulatory demands of human trials.
Further reading
For more on the latest research and industry developments, explore the Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do university-backed startup incubators provide more value to new companies than independent business development?
